Expression of TNF-receptor associated factor 2 correlates with poor progression-free survival time in ABC-like primary nodal diffuse large B-cell lymphomas

Histopathology

Volumn 52, Issue 5, 2008, Pages 578-584

  Van Galen, J C ^a   Muris, J J F ^a   Giroth, C P E ^a   Vos, W ^a   Ossenkoppele, G J ^a   Meijer, C J L M ^a   Oudejans, J J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Apoptosis; Diffuse; Large B cell; Lymphoma; TNF receptor associated factor 2

Indexed keywords

FLICE INHIBITORY PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; X LINKED INHIBITOR OF APOPTOSIS;

ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CYTOTOXIC T LYMPHOCYTE; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; GERMINAL CENTER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B-LYMPHOCYTES; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, DIRECT; GERMINAL CENTER; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISONE; RADIOTHERAPY, ADJUVANT; SURVIVAL RATE; TNF RECEPTOR-ASSOCIATED FACTOR 2; TUMOR MARKERS, BIOLOGICAL; VINCRISTINE;

EID: 41149112319     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2008.02970.x     Document Type: Article

References (36)

1. The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997 89 3909 3918.
2. Coiffier B. Monoclonal antibody as therapy for malignant lymphomas. C. R. Biol. 2006 329 241 254.
3. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002 108 153 164.
4. Kitada S, Pedersen IM, Schimmer AD et al. Dysregulation of apoptosis genes in hematopoietic malignancies. Oncogene 2002 21 3459 3474.
5. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000 403 503 511.
6. Shipp MA, Ross KN, Tamayo P et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat. Med. 2002 8 68 74.
7. Robertson JD, Gogvadze V, Zhivotovsky B et al. Distinct pathways for stimulation of cytochrome c release by etoposide. J. Biol. Chem. 2000 275 32438 32443.
8. Schwartz PS, Waxman DJ. Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumor cells. Mol. Pharmacol. 2001 60 1268 1279.
9. Gamen S, Anel A, Perez-Galan P et al. Doxorubicin treatment activates a Z-VAD-sensitive caspase, which causes deltapsim loss, caspase-9 activity, and apoptosis in Jurkat cells. Exp. Cell Res. 2000 258 223 235.
10. Henkels KM, Turchi JJ. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines. Cancer Res. 1999 59 3077 3083.
11. Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat. Immunol. 2002 3 221 227.
12. Gilmore TD. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 2006 25 6680 6684.
13. Barkett M, Gilmore TD. Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene 1999 18 6910 6924.
14. Dempsey PW, Doyle SE, He JQ et al. The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev. 2003 14 193 209.
15. Muris JJ, Cillessen SA, Vos W et al. Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas. Blood 2005 105 2916 2923.
16. Grech AP, Amesbury M, Chan T et al. TRAF2 differentially regulates the canonical and noncanonical pathways of NF-kappaB activation in mature B cells. Immunity 2004 21 629 642.
17. Chung JY, Park YC, Ye H et al. All TRAFs are not created equal: common and distinct molecular mechanisms of TRAF-mediated signal transduction. J. Cell Sci. 2002 115 679 688.
18. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ. 2003 10 45 65.
19. Mauro C, Crescenzi E, De Mattia R et al. Central role of the scaffold protein tumor necrosis factor receptor-associated factor 2 in regulating endoplasmic reticulum stress-induced apoptosis. J. Biol. Chem. 2006 281 2631 2638.
20. Bradley JR, Pober JS. Tumor necrosis factor receptor-associated factors (TRAFs). Oncogene 2001 20 6482 6491.
21. Xu C, Bailly-Maitre B, Reed JC. Endoplasmic reticulum stress: cell life and death decisions. J. Clin. Invest. 2005 115 2656 2664.
22. Yoneda T, Imaizumi K, Oono K et al. Activation of caspase-12, an endoplastic reticulum (ER) resident caspase, through tumor necrosis factor receptor-associated factor 2-dependent mechanism in response to the ER stress. J. Biol. Chem. 2001 276 13935 13940.
23. Kaneko M, Niinuma Y, Nomura Y. Activation signal of nuclear factor-kappa B in response to endoplasmic reticulum stress is transduced via IRE1 and tumor necrosis factor receptor-associated factor 2. Biol. Pharm. Bull. 2003 26 931 935.
24. Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). World Health Organization classification of tumours. Pathology and genetics of tumours of hematopoietic and lymphoid tissues. Lyon : IARC Press, 2001.
25. Muris JJ, Meijer CJ, Cillessen SA et al. Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas. Leukemia 2004 18 589 596.
26. Muris JJ, Ylstra B, Cillessen SA et al. Profiling of apoptosis genes allows for clinical stratification of primary nodal diffuse large B-cell lymphomas. Br. J. Haematol. 2007 136 38 47.
27. Wright G, Tan B, Rosenwald A et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc. Natl Acad. Sci. USA 2003 100 9991 9996.
28. Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004 103 275 282.
29. Zapata JM, Krajewska M, Krajewski S et al. TNFR-associated factor family protein expression in normal tissues and lymphoid malignancies. J. Immunol. 2000 165 5084 5096.
30. Davis RE, Brown KD, Siebenlist U et al. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J. Exp. Med. 2001 194 1861 1874.
31. Hu P, Han Z, Couvillon AD et al. Autocrine tumor necrosis factor alpha links endoplasmic reticulum stress to the membrane death receptor pathway through IRE1alpha-mediated NF-kappaB activation and down-regulation of TRAF2 expression. Mol. Cell. Biol. 2006 26 3071 3084.
32. Hetz C, Bernasconi P, Fisher J et al. Proapoptotic BAX and BAK modulate the unfolded protein response by a direct interaction with IRE1alpha. Science 2006 312 572 576.
33. Linder S, Shoshan MC. Lysosomes and endoplasmic reticulum: targets for improved, selective anticancer therapy. Drug Resist. Updat. 2005 8 199 204.
34. Jang YM, Kendaiah S, Drew B et al. Doxorubicin treatment in vivo activates caspase-12 mediated cardiac apoptosis in both male and female rats. FEBS Lett. 2004 577 483 490.
35. Ozoren N, El-Deiry WS. Cell surface death receptor signaling in normal and cancer cells. Semin. Cancer Biol. 2003 13 135 147.
36. Wajant H, Scheurich P. Tumor necrosis factor receptor-associated factor (TRAF) 2 and its role in TNF signaling. Int. J. Biochem. Cell Biol. 2001 33 19 32.